TPST-1495 is a novel oral therapy that inhibits signaling only at the tumor promoting EP2/EP4 receptors. In patients with heavily treated solid tumors, primarily MSS CRC, TPST-1495 had pharmacodynamic activity, a manageable safety profile, and a potential signal of activity consistent with the ...
小分子双拮抗剂TPST-1495的研究新药(IND)申请被FDA批准,开始对前列腺素驱动肿瘤的治疗进行临床研究,根据Tempest Therapeutics.1 的新闻稿,将启动一项Ia/Ib阶段试验,以评估TPST-149单独和联合检查点抑制剂治疗晚期实体瘤的安全性、耐受性、药代动力学、药效学和初步抗肿瘤活性。这项研究将包括一个剂量递增阶段,以确...